Seiya Takano, Natsuo Tomita, Mayu Kuno, Masanari Niwa, Akira Torii, Taiki Takaoka, Nozomi Kita, Dai Okazaki, Shintaro Yamamoto, Tatsuya Kawai, Chikao Sugie, Yasutaka Ogawa, Kenichi Matsumoto, Kaoru Uchiyama, Shinya Otsuka, Tooru Matsui, Akifumi Miyakawa, Tomoki Mizuno, Masato Iida, Motoki Tanikawa, Mitsuhito Mase, Akio Hiwatashi
We compared survival outcomes of high-dose concomitant boost radiotherapy (HDCBRT) and conventional dose radiotherapy (CRT) for newly diagnosed glioblastoma (GB). Patients treated with intensity-modulated radiation therapy for newly diagnosed GB were included. In HDCBRT, specific targets received 69, 60, and 51 Gy in 30 fractions, while 60 Gy in 30 fractions was administered with a standard radiotherapy method in CRT. Overall survival (OS) and progression-free survival (PFS) were compared using the Log-rank test, followed by multivariate Cox analysis...
April 23, 2024: Scientific Reports